Literature DB >> 10403924

Interferon-gamma (IFN-gamma)-dependent protection and synthesis of chemoattractants for mononuclear leucocytes caused by IL-12 in the lungs of mice infected with Cryptococcus neoformans.

K Kawakami1, M H Qureshi, T Zhang, Y Koguchi, K Shibuya, S Naoe, A Saito.   

Abstract

We have recently demonstrated that IL-12 induced cellular inflammatory responses consisting mainly of accumulation of mononuclear leucocytes in the lungs of mice infected with Cryptococcus neoformans and protected mice against fulminant infection. We examined the involvement of endogenously synthesized IFN-gamma in such a response by investigating the effects of a neutralizing monoclonal antibody against this cytokine. The latter treatment completely abrogated the positive effects of IL-12 on survival of infected mice and prevented IL-12-induced elimination of microbials from the lungs. Histopathological examination showed that accumulation of mononuclear leucocytes in the infected lungs caused by IL-12 was clearly inhibited by anti-IFN-gamma MoAb. We also examined the local production of mononuclear cell-attracting chemokines such as monocyte chemotactic protein-1 (MCP-1), regulated upon activation, normal T cell expressed and secreted (RANTES), macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta and IFN-gamma-inducible protein 10 (IP-10) in the lungs using a reverse transcriptase-polymerase chain reaction (RT-PCR) method. We found that these chemokines were not synthesized in the infected lungs, while IL-12 treatment markedly induced their production. Interestingly, neutralizing anti-IFN-gamma MoAb strongly suppressed IL-12-induced production of these chemokines. Similar results were obtained with MCP-1 and MIP-1alpha when their synthesis was measured at the protein level using respective ELISA kits. Our results indicate that IFN-gamma plays a central role in the protective effects of IL-12 by inducing mononuclear leucocyte-attracting chemokines and cellular inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403924      PMCID: PMC1905488          DOI: 10.1046/j.1365-2249.1999.00955.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

1.  Tissue-specific expression of murine IP-10 mRNA following systemic treatment with interferon gamma.

Authors:  S Narumi; L M Wyner; M H Stoler; C S Tannenbaum; T A Hamilton
Journal:  J Leukoc Biol       Date:  1992-07       Impact factor: 4.962

2.  RANTES and related chemokines activate human basophil granulocytes through different G protein-coupled receptors.

Authors:  S C Bischoff; M Krieger; T Brunner; A Rot; V von Tscharner; M Baggiolini; C A Dahinden
Journal:  Eur J Immunol       Date:  1993-03       Impact factor: 5.532

3.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages.

Authors:  C S Hsieh; S E Macatonia; C S Tripp; S F Wolf; A O'Garra; K M Murphy
Journal:  Science       Date:  1993-04-23       Impact factor: 47.728

4.  Differential regulation of interleukin-6, macrophage inflammatory protein-1, and JE/MCP-1 cytokine expression in macrophage cell lines.

Authors:  C A Martin; M E Dorf
Journal:  Cell Immunol       Date:  1991-06       Impact factor: 4.868

5.  Regulation of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor-1 by IFN-gamma, tumor necrosis factor-alpha, IgG aggregates, and cAMP in mouse mesangial cells.

Authors:  J A Satriano; K Hora; Z Shan; E R Stanley; T Mori; D Schlondorff
Journal:  J Immunol       Date:  1993-03-01       Impact factor: 5.422

6.  A role for gamma delta + T cells during experimental infection of mice with Leishmania major.

Authors:  J P Rosat; H R MacDonald; J A Louis
Journal:  J Immunol       Date:  1993-01-15       Impact factor: 5.422

Review 7.  Properties of the novel proinflammatory supergene "intercrine" cytokine family.

Authors:  J J Oppenheim; C O Zachariae; N Mukaida; K Matsushima
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

8.  Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1 beta.

Authors:  B Sherry; P Tekamp-Olson; C Gallegos; D Bauer; G Davatelis; S D Wolpe; F Masiarz; D Coit; A Cerami
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

9.  RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes.

Authors:  A Rot; M Krieger; T Brunner; S C Bischoff; T J Schall; C A Dahinden
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

10.  Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils.

Authors:  Y Kameyoshi; A Dörschner; A I Mallet; E Christophers; J M Schröder
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

View more
  20 in total

1.  Interleukin-12 regulates chemokine gene expression during the early immune response to Leishmania major.

Authors:  Colby Zaph; Phillip Scott
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

2.  Requirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice.

Authors:  K L Buchanan; H A Doyle
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Dendritic cell-based immunization ameliorates pulmonary infection with highly virulent Cryptococcus gattii.

Authors:  Keigo Ueno; Yuki Kinjo; Yoichiro Okubo; Kyoko Aki; Makoto Urai; Yukihiro Kaneko; Kiminori Shimizu; Dan-Ni Wang; Akiko Okawara; Takuya Nara; Kayo Ohkouchi; Yuki Mizuguchi; Susumu Kawamoto; Katsuhiko Kamei; Hideaki Ohno; Yoshihito Niki; Kazutoshi Shibuya; Yoshitsugu Miyazaki
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

Review 4.  Immune response and immunotherapy to Cryptococcus infections.

Authors:  Qing Zhou; William J Murphy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial.

Authors:  Joseph N Jarvis; Graeme Meintjes; Kevin Rebe; Gertrude Ntombomzi Williams; Tihana Bicanic; Anthony Williams; Charlotte Schutz; Linda-Gail Bekker; Robin Wood; Thomas S Harrison
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

6.  Type-I IFN signaling suppresses an excessive IFN-gamma response and thus prevents lung damage and chronic inflammation during Pneumocystis (PC) clearance in CD4 T cell-competent mice.

Authors:  Nicole Meissner; Steve Swain; Kate McInnerney; Soo Han; Allen G Harmsen
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

7.  The gamma interferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans.

Authors:  Gwo-Hsiao Chen; Roderick A McDonald; Jason C Wells; Gary B Huffnagle; Nicholas W Lukacs; Galen B Toews
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

8.  Interleukin-12 neutralization alters lung inflammation and leukocyte expression of CD80, CD86, and major histocompatibility complex class II in mice infected with Histoplasma capsulatum.

Authors:  J A Cain; G S Deepe
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

9.  Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production.

Authors:  Benjamin J Murdock; Gary B Huffnagle; Michal A Olszewski; John J Osterholzer
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

10.  CCR2 mediates conventional dendritic cell recruitment and the formation of bronchovascular mononuclear cell infiltrates in the lungs of mice infected with Cryptococcus neoformans.

Authors:  John J Osterholzer; Jeffrey L Curtis; Timothy Polak; Theresa Ames; Gwo-Hsiao Chen; Rod McDonald; Gary B Huffnagle; Galen B Toews
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.